New Delhi: Torrente Pharmaceuticals Ltd has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical products market Vonoprazan in India, which is used to treat and prevent the recurrence of ulcers (sores in the lining of the stomach or intestine) caused by certain types of bacteria, the company said in a statement on Wednesday.
Vonoprozan is a new potassium-competitive acid blocker (P-CAB), which is used for the treatment of acid-related gastroesophageal reflux disease (GERD).
Torrent will market Vonoprazan under its own brand, Kabvie, it said.
"We are delighted to commercialize this novel treatment for Indian patients. I am confident that the launch of Kabvie will help reduce the disease burden of GERD and further strengthen our gastrointestinal offering, increasing our position as a leading player within the Indian pharmaceutical market." said Aman Mehta, director of Torrent.
Commercialization of a drug generally refers to its manufacturing, marketing and distribution after due regulatory approval.
What is GERD?
GERD is a digestive disease in which stomach acid or bile irritates the lining of the esophagus. This is a chronic disease that occurs when stomach acid or bile flows into the esophagus and irritates the lining. Acid reflux and heartburn more than twice a week may indicate GERD.
According to a 2019 study published by the Indian Journal of Gastroenterology, the prevalence of GERD in the Indian population is around 8.2%, with a higher prevalence of around 11.1% in the urban population.
Currently, treatments such as pantoprazole (proton pump inhibitors) are used to treat GERD.
You're at Mint! India's number one news destination (Source: Press Gazette). To learn more about our trade coverage and market insights Click here!
Catch all the corporate news and updates on Live Mint. Download the Mint News App to obtain daily Market updates & Live business news.
Published: June 5, 2024, 10:22 pm IST
